This document summarizes recent updates on reversal agents for new oral anticoagulants (TSOACs). It discusses the benefits of TSOACs like easy compliance and short half-lives, but also the challenges they present for reversing bleeding risks without established antidotes. Potential reversal agents discussed include prothrombin complex concentrate, activated prothrombin complex concentrate, recombinant factor VIIa, and the small molecule aripazine. Specific reversal agents idarucizumab for dabigatran and andexanet alfa for factor Xa inhibitors are presented, along with consensus recommendations for when and how to reverse bleeding risks from TSOACs.